Myeloma UK is pleased to announce that MUK nine is the latest trial in the Myeloma UK Clinical Trial Network (CTN) open to patient recruitment.
The aim of MUK nine is to stratify treatment for high-risk myeloma patients. Up to 700 newly diagnosed myeloma patients will be recruited and screened at the Institute of Cancer Research (ICR), London. Those determined to have high-risk myeloma on the basis of genetic analysis will be progressed to the Phase II MUK nine trial. This trial will assess the effectiveness of a new treatment combination; bortezomib, lenalidomide, daratumumab and dexamethasone with low dose cyclophosphamide in conjunction with an autologous stem cell transplant.
In addition, this trial will increase understanding of the genetic basis of myeloma, which may aid the delivery of stratified treatments for all myeloma patients in the future.
The Myeloma UK CTN was originally set up to provide access to promising myeloma drugs and to accelerate the process for the approval and availability of new drugs to patients on the NHS.